Filtros de búsqueda

Lista de obras de Alexander M Menzies

(18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.

artículo científico publicado en 2012

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

artículo científico publicado en 2019

A case series of immune checkpoint inhibitor induced diabetes mellitus (ICI-DM).

artículo científico publicado en 2018

A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy

artículo científico publicado en 2017

Abstract 2650: In depth immune profiling of the response of melanoma to MAPK inhibition

Abstract 5025: Immune expression profiling of MAPK inhibitor resistant tumors based upon mechanisms of resistance

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

artículo científico publicado en 2015

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma

artículo científico publicado en 2016

Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial

scientific article published on 25 September 2019

Advanced cancer patients' attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study.

artículo científico publicado en 2016

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.

artículo científico publicado en 2018

Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma

scientific article published on 29 November 2019

Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA

artículo científico publicado en 2022

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.

artículo científico publicado en 2016

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection

article

Applying adjuvant therapy for melanoma into clinical practice

artículo científico publicado en 2020

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.

artículo científico publicado en 2018

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

artículo científico publicado en 2018

BRAF inhibitor activity in V600R metastatic melanoma

artículo científico publicado en 2012

BRAF inhibitor activity in V600R metastatic melanoma--response.

artículo científico publicado en 2013

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

artículo científico publicado en 2014

BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.

artículo científico publicado en 2013

Biology and treatment of BRAF mutant metastatic melanoma

artículo científico publicado en 2016

CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment

artículo científico publicado en 2018

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series

artículo científico publicado en 2016

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

artículo científico publicado en 2014

Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes

artículo científico publicado en 2019

Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy

scientific article published on 16 October 2020

Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy

article

Circulating tumor DNA (ctDNA) using Guardant360 to predict response in BRAF V600 WT metastatic melanoma (MM) patients (pts) receiving immune checkpoint inhibitors (ICI).

artículo científico publicado en 2020

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.

artículo científico publicado en 2017

Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion

artículo científico publicado en 2015

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

artículo científico publicado en 2017

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors

artículo científico publicado en 2015

Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab

artículo científico publicado en 2020

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients

artículo científico publicado en 2019

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

artículo científico publicado en 2018

Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma

scientific article published on 02 November 2019

Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making

artículo científico publicado en 2016

Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.

artículo científico publicado en 2014

Corrigendum to “Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*” [Eur J Cancer 91 (2018) 116–124]

artículo científico publicado en 2018

Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

artículo científico publicado en 2016

Cost-effectiveness analysis of PET/CT surveillance imaging to detect systemic recurrence in resected stage III melanoma: study protocol

artículo científico publicado en 2020

Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma

scientific article published on 28 January 2020

Current management of patients with melanoma who are found to be sentinel node-positive

scientific article published on 30 October 2019

Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma

artículo científico

Dabrafenib and its potential for the treatment of metastatic melanoma

artículo científico publicado en 2012

Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma

artículo científico publicado en 2014

Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA

artículo científico publicado en 2020

Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies

artículo científico publicado en 2020

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

artículo científico publicado en 2019

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma

artículo científico publicado en 2019

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

scientific article published on 24 April 2012

Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring--The TADE Study

article

Durability of response to immune checkpoint inhibitors (ICI) in metastatic Merkel cell carcinoma (mMCC) after treatment cessation.

artículo científico publicado en 2021

Duration of immunotherapy - should we continue ad infinitum?

artículo científico publicado en 2020

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.

artículo científico publicado en 2017

Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment.

artículo científico publicado en 2014

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

artículo científico publicado en 2017

Efficacy of immune checkpoint inhibitors for in-transit melanoma

scientific article published on 01 May 2020

Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas

artículo científico publicado en 2014

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

artículo científico publicado en 2019

Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors.

artículo científico publicado en 2014

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients

artículo científico publicado en 2017

Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.

artículo científico publicado en 2015

Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis.

artículo científico publicado en 2018

False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma

scientific article published on 25 March 2019

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

article

Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma.

artículo científico publicado en 2014

Has the melanoma information tsunami become a maelstrom?

scholarly article by John F Thompson & Alexander M Menzies published December 2017 in Melanoma management

Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report

artículo científico publicado en 2020

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

artículo científico publicado en 2019

Immune Checkpoint Inhibitors for Brain Metastases

artículo científico publicado en 2017

Immune checkpoint inhibitors in challenging populations

artículo científico publicado en 2017

Immune mediated neuropathy following checkpoint immunotherapy

artículo científico publicado en 2017

Immunotherapy-related acute kidney injury: Kidney biopsy or not?

scientific article published on 12 January 2020

Incidence of new primary melanomas after diagnosis of stage III and IV melanoma.

artículo científico publicado en 2013

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies

scientific article published on 03 March 2019

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

artículo científico publicado en 2014

Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients

scientific article published on 31 October 2018

Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors

artículo científico publicado en 2020

Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma

scientific article published on 06 January 2014

Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment

scientific article published on 01 May 2019

Intra-patient heterogeneity of BRAF mutation status: fact or fiction?

artículo científico publicado en 2013

Intrapatient homogeneity of BRAFV600E expression in melanoma.

artículo científico publicado en 2014

Intratumoural immunotherapies in oncology

scientific article published on 18 January 2020

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

artículo científico publicado en 2015

Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread

Leptomeningeal melanoma-A case series in the era of modern systemic therapy

artículo científico publicado en 2017

Long-Term Follow-Up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients With Advanced Melanoma: KEYNOTE-029 Part 1B

scientific article published on 30 June 2020

Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors

scientific article published on 22 April 2020

Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia

artículo científico publicado en 2020

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma

artículo científico publicado en 2017

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis

artículo científico publicado en 2020

Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma.

artículo científico publicado en 2017

Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis

artículo científico publicado en 2021

Molecular biomarkers of prognosis in melanoma

artículo científico publicado en 2013

Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis

artículo científico publicado en 2020

Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.

artículo científico publicado en 2017

Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

scientific article published on 03 June 2019

Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

scientific article published on 01 July 2019

New combinations and immunotherapies for melanoma: latest evidence and clinical utility.

artículo científico

Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation - Authors' reply

scientific article published on 01 August 2018

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.

artículo científico publicado en 2016

Optimum dosing of ipilimumab in melanoma: too little, too late?

scientific article published on 27 March 2017

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

artículo científico publicado en 2014

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors

artículo científico publicado en 2017

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.

artículo científico publicado en 2015

PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma

artículo científico publicado en 2016

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

article

Paradoxical oncogenesis: are all BRAF inhibitors equal?

artículo científico publicado en 2013

Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre

Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib

artículo científico publicado en 2013

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia

artículo científico publicado en 2019

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

artículo científico publicado en 2016

Preferences for Immunotherapy in Melanoma: A Systematic Review

artículo científico publicado en 2019

Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients

artículo científico publicado en 2020

Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials

artículo científico publicado en 2019

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

artículo científico publicado en 2011

Radiological manifestations of immune-related adverse effects observed in patients with melanoma undergoing immunotherapy.

artículo científico publicado en 2017

Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies

Recent Developments in Melanoma Therapy.

artículo científico publicado en 2016

Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond

artículo científico

Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy

artículo científico publicado en 2020

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

artículo científico publicado en 2018

Reply to M. Perier-Muzet et al

scientific article published on 02 September 2014

Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy.

artículo científico publicado en 2016

Response to Letter to the Editor for "Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes"

scientific article published on 19 March 2020

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.

artículo científico publicado en 2017

Sentinel node biopsy for melanoma: The medical oncology perspective

Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy

artículo científico publicado en 2019

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

artículo científico

Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma

Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy.

artículo científico publicado en 2017

Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies

artículo científico publicado en 2017

Systemic treatment for BRAF-mutant melanoma: where do we go next?

artículo científico publicado en 2014

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations

artículo científico publicado en 2019

The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma

scientific article published on 29 November 2019

The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients - A Potential Paradigm Shift in Management

artículo científico publicado en 2020

The molecular profile of metastatic melanoma in Australia

artículo científico publicado en 2016

The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.

artículo científico publicado en 2014

The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.

artículo científico publicado en 2017

Thyroid toxicity following immune checkpoint inhibitor treatment in advanced cancer

artículo científico publicado en 2020

Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy

artículo científico publicado en 2018

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition

scientific article published on 20 April 2020

Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma

artículo científico publicado en 2020

Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma

scientific article published on 14 November 2020

Tumor mutation burden and structural chromosomal aberrations are not associated with T-cell density or patient survival in acral, mucosal, and cutaneous melanomas

scientific article published on 11 September 2020

Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility

artículo científico publicado en 2018

Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases

scientific article published on 14 June 2020

bcGST-an interactive bias-correction method to identify over-represented gene-sets in boutique arrays

scientific article published on 01 April 2019

sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

artículo científico publicado en 2016

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda